nmsg

News

31 Thymic carcinoma Phase II data of Milciclib, a kinase inhibitor discovered at Nerviano Medical Sciences, disclosed at the medical oncology meeting AIOM 2014 Ott 28, 2014
32 Novel JAK2 inhibitors discovered by Nerviano Medical Sciences featured on the cover of Bioorganic & Medicinal Chemistry Set 30, 2014
33 Nerviano Medical Sciences' partner Ignyta announces interim data from RXDX-101 phase I clinical trial at 2014 ESMO congress Set 30, 2014
34 Two young researchers of Nerviano Medical Sciences winners of the award “Premio Società Italiana di Farmacologia- Farmindustria per Ricerche Farmacologiche” 2014 Set 17, 2014
35 Ignyta and Nerviano announce license agreement for two first-in-class kinase inhibitors Ago 4, 2014
36 Cellectis e Accelera siglano un accordo per il completamento degli studi preclinici di UCART19 di Cellectis, una nuova e promettente terapia per per leucemie e linfomi Giu 9, 2014
37 Phase I data of RXDX-101, a kinase inhibitor discovered at Nerviano Medical Sciences, in patients with advanced solid tumors with relevant molecular alterations to be disclosed at 2014 ASCO Mag 16, 2014
38 Phase II data of Nerviano Medical Science’s kinase inhibitor Milciclib in patients with thymic carcinoma to be reported at 2014 ASCO Mag 16, 2014
39 Pubblicazioni scientifiche di NMS Mar 26, 2014
40 Nerviano Medical Sciences to present a novel orally available selective small molecule Cdc7 inhibitor at the AACR Annual Meeting 2014 Feb 25, 2014

Pagina 4 di 5

Per offrirti un'esperienza di navigazione ottimizzata NMS Group e le società controllate utilizzano cookies, anche di terze parti.
Proseguendo con la navigazione acconsenti al loro impiego in conformità della nostra  
Cookie Policy.